Cargando…
Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission
Behavioral conditioning and expectation can have profound impact on animal and human physiology. Placebo, administered under positive expectation in clinical trials, can have potent effects on disease pathology, obscuring active medications. Emerging evidence suggests placebo-responsive neurotransmi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054677/ https://www.ncbi.nlm.nih.gov/pubmed/34716408 http://dx.doi.org/10.1038/s41380-021-01365-x |
_version_ | 1784697243859681280 |
---|---|
author | Prossin, Alan Koch, Alisa Campbell, Phillip Laumet, Geoffroy Stohler, Christian S. Dantzer, Robert Zubieta, Jon-Kar |
author_facet | Prossin, Alan Koch, Alisa Campbell, Phillip Laumet, Geoffroy Stohler, Christian S. Dantzer, Robert Zubieta, Jon-Kar |
author_sort | Prossin, Alan |
collection | PubMed |
description | Behavioral conditioning and expectation can have profound impact on animal and human physiology. Placebo, administered under positive expectation in clinical trials, can have potent effects on disease pathology, obscuring active medications. Emerging evidence suggests placebo-responsive neurotransmitter systems (e.g., endogenous opioid) regulate immune function by manipulating inflammatory proteins including IL-18, a potent pro-inflammatory, nociceptive cytokine implicated in pathophysiology of various diseases. Validation that neuroimmune interactions involving brain μ-opioid receptor (MOR) activity and plasma IL-18 underlie placebo analgesic expectation could have widespread clinical applications. Unfortunately, current lack of mechanistic clarity obfuscates clinical translation. To elucidate neuroimmune interactions underlying placebo analgesia, we exposed 37 healthy human volunteers to a standardized pain challenge on each of 2 days within a Positron Emission Tomography (PET) neuroimaging paradigm using the MOR selective radiotracer, (11)C-Carfentanil (CFN). Each day volunteers received an intervention (placebo under analgesic expectation or no treatment), completed PET scanning, and rated their pain experience. MOR BP(ND) parametric maps were generated from PET scans using standard methods. Results showed placebo reduced plasma IL-18 during pain (W(74) = −3.7, p < 0.001), the extent correlating with reduction in pain scores. Placebo reduction in IL-18 covaried with placebo-induced endogenous opioid release in the left nucleus accumbens (T(148) = 3.33; p(uncorr) < 0.001) and left amygdala (T(148) = 3.30; p(uncorr) < 0.001). These findings are consistent with a modulating effect of placebo (under analgesic expectation in humans) on a potent nociceptive, pro-inflammatory cytokine (IL-18) and underlying relationships with endogenous opioid activity, a neurotransmitter system critically involved in pain, stress, and mood regulation. |
format | Online Article Text |
id | pubmed-9054677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90546772022-05-01 Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission Prossin, Alan Koch, Alisa Campbell, Phillip Laumet, Geoffroy Stohler, Christian S. Dantzer, Robert Zubieta, Jon-Kar Mol Psychiatry Immediate Communication Behavioral conditioning and expectation can have profound impact on animal and human physiology. Placebo, administered under positive expectation in clinical trials, can have potent effects on disease pathology, obscuring active medications. Emerging evidence suggests placebo-responsive neurotransmitter systems (e.g., endogenous opioid) regulate immune function by manipulating inflammatory proteins including IL-18, a potent pro-inflammatory, nociceptive cytokine implicated in pathophysiology of various diseases. Validation that neuroimmune interactions involving brain μ-opioid receptor (MOR) activity and plasma IL-18 underlie placebo analgesic expectation could have widespread clinical applications. Unfortunately, current lack of mechanistic clarity obfuscates clinical translation. To elucidate neuroimmune interactions underlying placebo analgesia, we exposed 37 healthy human volunteers to a standardized pain challenge on each of 2 days within a Positron Emission Tomography (PET) neuroimaging paradigm using the MOR selective radiotracer, (11)C-Carfentanil (CFN). Each day volunteers received an intervention (placebo under analgesic expectation or no treatment), completed PET scanning, and rated their pain experience. MOR BP(ND) parametric maps were generated from PET scans using standard methods. Results showed placebo reduced plasma IL-18 during pain (W(74) = −3.7, p < 0.001), the extent correlating with reduction in pain scores. Placebo reduction in IL-18 covaried with placebo-induced endogenous opioid release in the left nucleus accumbens (T(148) = 3.33; p(uncorr) < 0.001) and left amygdala (T(148) = 3.30; p(uncorr) < 0.001). These findings are consistent with a modulating effect of placebo (under analgesic expectation in humans) on a potent nociceptive, pro-inflammatory cytokine (IL-18) and underlying relationships with endogenous opioid activity, a neurotransmitter system critically involved in pain, stress, and mood regulation. Nature Publishing Group UK 2021-10-29 2022 /pmc/articles/PMC9054677/ /pubmed/34716408 http://dx.doi.org/10.1038/s41380-021-01365-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Immediate Communication Prossin, Alan Koch, Alisa Campbell, Phillip Laumet, Geoffroy Stohler, Christian S. Dantzer, Robert Zubieta, Jon-Kar Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission |
title | Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission |
title_full | Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission |
title_fullStr | Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission |
title_full_unstemmed | Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission |
title_short | Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission |
title_sort | effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission |
topic | Immediate Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054677/ https://www.ncbi.nlm.nih.gov/pubmed/34716408 http://dx.doi.org/10.1038/s41380-021-01365-x |
work_keys_str_mv | AT prossinalan effectsofplaceboadministrationonimmunemechanismsandrelationshipswithcentralendogenousopioidneurotransmission AT kochalisa effectsofplaceboadministrationonimmunemechanismsandrelationshipswithcentralendogenousopioidneurotransmission AT campbellphillip effectsofplaceboadministrationonimmunemechanismsandrelationshipswithcentralendogenousopioidneurotransmission AT laumetgeoffroy effectsofplaceboadministrationonimmunemechanismsandrelationshipswithcentralendogenousopioidneurotransmission AT stohlerchristians effectsofplaceboadministrationonimmunemechanismsandrelationshipswithcentralendogenousopioidneurotransmission AT dantzerrobert effectsofplaceboadministrationonimmunemechanismsandrelationshipswithcentralendogenousopioidneurotransmission AT zubietajonkar effectsofplaceboadministrationonimmunemechanismsandrelationshipswithcentralendogenousopioidneurotransmission |